Jul 5, 2020 11:32PM Lumpie wrote:Efficacy and Safety of T-DM1 + Capecitabine vs T-DM1 Alone in Previously Treated ERBB2+ Metastatic Breast Cancer
- JAMA Oncology
- The authors of this phase I/II randomized clinical trial of 161 patients with previously treated ERBB2-positive metastatic breast cancer compared trastuzumab emtansine (T-DM1) with T-DM1 plus capecitabine. The overall response rate was numerically higher with combination therapy (44% vs 36%; P = .34). The median progression-free survival was similar between groups. Toxicity was higher with the addition of capecitabine, and more patients discontinued treatment due to adverse events in the combination arm compared with the T-DM1 monotherapy arm.
- Chemotherapy adds only modest potential benefit to T-DM1 while increasing toxicity.